HER2 Vaccine for Locally Advanced Breast Cancer
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Breast Cancer|HER2-positive Breast Cancer
DRUG: HER2 Vaccine
Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0, Number of adverse events as assessed by the NCI CTCAE v. 5.0, through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)|Immune Response, Humoral immune response will be measured by ELISA quantification of IgM and IgG antibodies to HER2 (597-626) and HER2 (266-296)., through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.